Reducing side effects,
promoting recovery.
Photobiomodulation (PBM) with the ATP38 offers advanced therapeutic support for oncology patients, helping to minimize the side effects of conventional treatments, accelerate tissue regeneration, and improve quality of life during and after therapy.
Reducing side effects,
promoting recovery.
Photobiomodulation (PBM) with the ATP38 offers advanced therapeutic support for oncology patients, helping to minimize the side effects of conventional treatments, accelerate tissue regeneration, and improve quality of life during and after therapy.
the oncology clinical book
Prevention and treatment of oral mucositis
Relief of peripheral neuropathic pain
Reduction of xerostomia and mucosal inflammation
Improved post-surgical healing and tissue regeneration
Support for physical and emotional well-being
the oncology clinical book
Prevention and treatment of oral mucositis
Relief of peripheral neuropathic pain
Reduction of xerostomia and mucosal inflammation
Improved post-surgical healing and tissue regeneration
Support for physical and emotional well-being
Dr. Joel Epstein, DMD, MSD
Dr. Joel Epstein, DMD, MSD
Preventive treatment following chemotherapy sessions
Treatment of epitheliitis with a session of PBM prior to the chemotherapy session.
Curative treatment following chemotherapy sessions
Treatment of a Grade III epitheliitis after 5 weeks of radiotherapy, progress after 4 sessions over 2 weeks.
7 studies
1. PBM to Prevent Oral Side Effects in Head & Neck Cancer. A randomized, single-blind RCT with 53 patients found PBM significantly delayed and reduced oral mucositis, preserved salivary function, and decreased pain and dysgeusia.
2. From molecular mechanisms to clinical applications: A comprehensive review of photobiomodulation in cancer treatment. Read more
3. Cost-effectiveness of photobiomodulation therapy for the prevention and management of cancer treatment toxicities: A systematic review. Read more
4. A Pilot Study Comparing Intraoral and Transcutaneous Photobiomodulation for Oral Mucositis in Head and Neck Cancer Patients. Read more
5. WALT Position Paper (2022 Consensus). Endorses PBM for preventing/treating mucositis, dermatitis, dysphagia, xerostomia, lymphedema, and neuropathy, with evidence-based dosimetry guidelines.
6. Chemotherapy-Induced Oral Mucositis: A 2020 meta-analysis. Found PBM significantly reduces mucositis severity, duration, and pain, but highlights the need for standardized parameters.
7. Peripheral Neuropathy & Lymphedema – NEUROLASER Pilot RCT. In breast cancer patients, PBM reduced neuropathy symptoms, improved physical function, and quality of life.
3 studies
1. In vitro/Animal Tumor-Stimulation Concerns. Most studies show PBM does not enhance tumor growth; high doses rarely showed growth stimulation.
2. Safety & Tumor Risk – Systematic Review (67 studies, April 2020). Concluded PBM is safe and may improve survival when used correctly.
3. Safety and efficacy of photobiomodulation therapy in oncology: A systematic review. Read more
Preventive treatment following chemotherapy sessions
Treatment of epitheliitis with a session of PBM prior to the chemotherapy session.
Curative treatment following chemotherapy sessions
Treatment of a Grade III epitheliitis after 5 weeks of radiotherapy, progress after 4 sessions over 2 weeks.
7 studies
1. PBM to Prevent Oral Side Effects in Head & Neck Cancer. A randomized, single-blind RCT with 53 patients found PBM significantly delayed and reduced oral mucositis, preserved salivary function, and decreased pain and dysgeusia.
2. From molecular mechanisms to clinical applications: A comprehensive review of photobiomodulation in cancer treatment. Read more
3. Cost-effectiveness of photobiomodulation therapy for the prevention and management of cancer treatment toxicities: A systematic review. Read more
4. A Pilot Study Comparing Intraoral and Transcutaneous Photobiomodulation for Oral Mucositis in Head and Neck Cancer Patients. Read more
5. WALT Position Paper (2022 Consensus). Endorses PBM for preventing/treating mucositis, dermatitis, dysphagia, xerostomia, lymphedema, and neuropathy, with evidence-based dosimetry guidelines.
6. Chemotherapy-Induced Oral Mucositis: A 2020 meta-analysis. Found PBM significantly reduces mucositis severity, duration, and pain, but highlights the need for standardized parameters.
7. Peripheral Neuropathy & Lymphedema – NEUROLASER Pilot RCT. In breast cancer patients, PBM reduced neuropathy symptoms, improved physical function, and quality of life.
3 studies
1. In vitro/Animal Tumor-Stimulation Concerns. Most studies show PBM does not enhance tumor growth; high doses rarely showed growth stimulation.
2. Safety & Tumor Risk – Systematic Review (67 studies, April 2020). Concluded PBM is safe and may improve survival when used correctly.
3. Safety and efficacy of photobiomodulation therapy in oncology: A systematic review. Read more
